{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T20:40:26Z","timestamp":1758746426168,"version":"3.44.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40268-025-00519-4","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T18:26:24Z","timestamp":1754677584000},"page":"263-274","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of Pharmacokinetics and Safety with Bioequivalence of the Nitroglycerin Sublingual Tablets of Two Formulations in Chinese Healthy Subjects: A Bioequivalence Study"],"prefix":"10.1007","volume":"25","author":[{"given":"Qinjiao","family":"Fu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunqi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanzhu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiufeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2121-7025","authenticated-orcid":false,"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"519_CR1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1046\/j.1440-1681.2000.03240.x","volume":"27","author":"N Marsh","year":"2000","unstructured":"Marsh N, Marsh A. A short history of nitroglycerine and nitric oxide in pharmacology and physiology. Clin Exp Pharmacol Physiol. 2000;27:313\u20139. https:\/\/doi.org\/10.1046\/j.1440-1681.2000.03240.x.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"519_CR2","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1056\/NEJMsa063904","volume":"355","author":"F Murad","year":"2006","unstructured":"Murad F. Nitric oxide and cyclic GMP in cell signaling and drug development. N Engl J Med. 2006;355:2003\u201311. https:\/\/doi.org\/10.1056\/NEJMsa063904.","journal-title":"N Engl J Med"},{"key":"519_CR3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/bcp.13804","volume":"85","author":"K Zhou","year":"2019","unstructured":"Zhou K, Parker JD. The role of vascular endothelium in nitroglycerin-mediated vasodilation. Br J Clin Pharmacol. 2019;85:377\u201384. https:\/\/doi.org\/10.1111\/bcp.13804.","journal-title":"Br J Clin Pharmacol"},{"key":"519_CR4","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","volume":"33","author":"JJV McMurray","year":"2012","unstructured":"Authors\/Task Force Members, McMurray JJV, Adamopoulos S, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787\u2013847. https:\/\/doi.org\/10.1093\/eurheartj\/ehs104.","journal-title":"Eur Heart J"},{"key":"519_CR5","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ajem.2020.03.062","volume":"44","author":"K Stemple","year":"2021","unstructured":"Stemple K, DeWitt KM, Porter BA, et al. High-dose nitroglycerin infusion for the management of sympathetic crashing acute pulmonary edema (SCAPE): a case series. Am J Emerg Med. 2021;44:262\u20136. https:\/\/doi.org\/10.1016\/j.ajem.2020.03.062.","journal-title":"Am J Emerg Med"},{"key":"519_CR6","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000086629.67552.3A","author":"TB Graboys","year":"2003","unstructured":"Graboys TB, Lown B. Nitroglycerin: the \u201cmini\u201d wonder drug. Circulation. 2003. https:\/\/doi.org\/10.1161\/01.CIR.0000086629.67552.3A.","journal-title":"Circulation"},{"key":"519_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1161\/CIRCULATIONAHA.116.025856","volume":"136","author":"KN Asrress","year":"2017","unstructured":"Asrress KN, Williams R, Lockie T, et al. Physiology of angina and its alleviation with nitroglycerin: insights from invasive catheter laboratory measurements during exercise. Circulation. 2017;136:24\u201334. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.025856.","journal-title":"Circulation"},{"key":"519_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1365-2125.1977.tb00703.x","volume":"4","author":"H Blumenthal","year":"1977","unstructured":"Blumenthal H, Fung H, McNiff E, Yap S. Plasma nitroglycerin levels after sublingual, oral and topical administration. Br J Clin Pharmacol. 1977;4:241\u20132. https:\/\/doi.org\/10.1111\/j.1365-2125.1977.tb00703.x.","journal-title":"Br J Clin Pharmacol"},{"key":"519_CR9","doi-asserted-by":"publisher","first-page":"340","DOI":"10.22270\/jddt.v8i6-s.2097","volume":"8","author":"PP Pawar","year":"2018","unstructured":"Pawar PP, Ghorpade HS, Kokane BA. Sublingual route for systemic drug delivery. J Drug Deliv Ther. 2018;8:340\u20133. https:\/\/doi.org\/10.22270\/jddt.v8i6-s.2097.","journal-title":"J Drug Deliv Ther."},{"key":"519_CR10","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/oxfordjournals.eurheartj.a062121","volume":"7","author":"G Nyberg","year":"1986","unstructured":"Nyberg G. Onset time of action and duration up to 3 hours of nitroglycerin in buccal, sublingual and transdermal form. Eur Heart J. 1986;7:673\u20138. https:\/\/doi.org\/10.1093\/oxfordjournals.eurheartj.a062121.","journal-title":"Eur Heart J"},{"key":"519_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1136\/hrt.30.3.407","volume":"30","author":"M Arborelius","year":"1968","unstructured":"Arborelius M, Lecerof H, Malm A, Malmborg RO. Acute effect of nitroglycerin on haemodynamics of angina pectoris. Heart. 1968;30:407\u201311. https:\/\/doi.org\/10.1136\/hrt.30.3.407.","journal-title":"Heart"},{"key":"519_CR12","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3389\/fphar.2019.01328","volume":"10","author":"S Hua","year":"2019","unstructured":"Hua S. Advances in nanoparticulate drug delivery approaches for sublingual and buccal administration. Front Pharmacol. 2019;10:1328. https:\/\/doi.org\/10.3389\/fphar.2019.01328.","journal-title":"Front Pharmacol"},{"key":"519_CR13","doi-asserted-by":"publisher","first-page":"e742","DOI":"10.4088\/JCP.15f10094","volume":"76","author":"C Andrade","year":"2015","unstructured":"Andrade C. Bioequivalence of generic drugs: a simple explanation for a US Food and Drug Administration requirement: (clinical and practical psychopharmacology). J Clin Psychiatry. 2015;76:e742\u20134. https:\/\/doi.org\/10.4088\/JCP.15f10094.","journal-title":"J Clin Psychiatry"},{"key":"519_CR14","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/00045391-199608000-00006","volume":"3","author":"LI Harrison","year":"1996","unstructured":"Harrison LI, Riedel DJ, Machacek JH, et al. Bioequivalence comparison of two drug-in-adhesive transdermal nitroglycerin patches. Am J Ther. 1996;3:580\u20135. https:\/\/doi.org\/10.1097\/00045391-199608000-00006.","journal-title":"Am J Ther"},{"key":"519_CR15","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1023\/A:1011942213508","volume":"15","author":"B Auclair","year":"1998","unstructured":"Auclair B, Sirois G, Ngoc AH, Ducharme MP. Novel pharmacokinetic modelling of transdermal nitroglycerin. Pharm Res. 1998;15:614\u20139. https:\/\/doi.org\/10.1023\/A:1011942213508.","journal-title":"Pharm Res"},{"key":"519_CR16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/MBP.0000000000000267","volume":"22","author":"M Liang","year":"2017","unstructured":"Liang M, Xu S, Luo S, et al. Correlation between ambulatory blood pressure variability and vasodilator function in middle-aged normotensive individuals. Blood Press Monit. 2017;22:355\u201363. https:\/\/doi.org\/10.1097\/MBP.0000000000000267.","journal-title":"Blood Press Monit"},{"key":"519_CR17","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1023\/a:1016468018478","volume":"13","author":"VP Shah","year":"1996","unstructured":"Shah VP, Yacobi A, Barr WH, et al. Evaluation of orally administered highly variable drugs and drug formulations. Pharm Res. 1996;13:1590\u20134. https:\/\/doi.org\/10.1023\/a:1016468018478.","journal-title":"Pharm Res"},{"key":"519_CR18","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1208\/s12248-012-9406-x","volume":"14","author":"BM Davit","year":"2012","unstructured":"Davit BM, Chen M-L, Conner DP, et al. Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US Food and Drug Administration. AAPS J. 2012;14:915\u201324. https:\/\/doi.org\/10.1208\/s12248-012-9406-x.","journal-title":"AAPS J"},{"key":"519_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2885.2012.01372.x","volume":"35","author":"R Gehring","year":"2012","unstructured":"Gehring R, Martinez M. Assessing product bioequivalence for extended-release formulations and drugs with long half-lives: assessing product bioequivalence for extended-release formulations. J Vet Pharmacol Ther. 2012;35:3\u20139. https:\/\/doi.org\/10.1111\/j.1365-2885.2012.01372.x.","journal-title":"J Vet Pharmacol Ther"},{"key":"519_CR20","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1161\/01.CIR.59.3.585","volume":"59","author":"PW Armstrong","year":"1979","unstructured":"Armstrong PW, Armstrong JA, Marks GS. Blood levels after sublingual nitroglycerin. Circulation. 1979;59:585\u20138. https:\/\/doi.org\/10.1161\/01.CIR.59.3.585.","journal-title":"Circulation"},{"key":"519_CR21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1001\/jama.2016.18977","volume":"317","author":"JJM Van Delden","year":"2017","unstructured":"Van Delden JJM, Van Der Graaf R. Revised CIOMS international ethical guidelines for health-related research involving humans. JAMA. 2017;317:135. https:\/\/doi.org\/10.1001\/jama.2016.18977.","journal-title":"JAMA"},{"key":"519_CR22","doi-asserted-by":"publisher","first-page":"725","DOI":"10.2165\/11318040-000000000-00000","volume":"48","author":"L Tothfalusi","year":"2009","unstructured":"Tothfalusi L, Endrenyi L, Arieta AG. Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence. Clin Pharmacokinet. 2009;48:725\u201343. https:\/\/doi.org\/10.2165\/11318040-000000000-00000.","journal-title":"Clin Pharmacokinet"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-025-00519-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-025-00519-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-025-00519-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T20:03:17Z","timestamp":1758744197000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-025-00519-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["519"],"URL":"https:\/\/doi.org\/10.1007\/s40268-025-00519-4","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"type":"print","value":"1174-5886"},{"type":"electronic","value":"1179-6901"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"assertion":[{"value":"8 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by the Zhejiang Province Leading Geese Plan (2024C03099) and the Key R&D Program of Hangzhou Science and Technology Bureau (20241203A17).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors affirm that there are no potential conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study was approved by the Medical Ethics Review Committee of Hangzhou Red Cross Hospital (approval number: 2023-002-001).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants in this study voluntarily took part after fully understanding the purpose, process, and potential risks. Before the study began, they signed an informed consent form confirming their understanding of the research, its risks and benefits, and their rights, including the right to withdraw at any time. Participants\u2019 information will be kept confidential, and data will be analyzed anonymously to protect their privacy. This study follows ethical guidelines and has been approved by the ethics committee.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All authors have consented to the publication of this manuscript. The authors confirm that the manuscript has not been published elsewhere and is not under consideration by any other publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data that support the findings of this study are available from Neoform Biopharmaceutical Co., Ltd. However, restrictions apply to the availability of these data, as they were used under license for the current study and are not publicly available. Nonetheless, data can be obtained from the corresponding author upon reasonable request and with permission from Neoform Biopharmaceutical Co., Ltd.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Qinjiao Fu wrote the manuscript; Ying Wang, Yingying Xu, and Chunqi Huang designed the research; Yuan Yuan, Yu Wang, and Bin Zhu performed the research; Yanzhu Liu and Fang Tian analyzed the data; Xiufeng Xu and Lei Yang contributed new reagents\/analytical tools.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}